Clinical Trial Update: An Eight-week Study Evaluating the Efficacy and Tolerability of Two Doses of SSR149415 in Outpatients With Generalized Anxiety Disorder [Phase 2]

View source ↗

Summary

Phase 2 trial assessing the efficacy and tolerability of two doses of SSR149415 in outpatients with generalized anxiety disorder; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Generalized Anxiety Disorder

Drugs mentioned

• SSR149415

Snippet

Sponsor: Sanofi | Conditions: Anxiety Disorders | Phase 2 | Status: COMPLETED